Equibles does not estimate personal net worth.
Get an email with a short summary when Denali Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get DNLI alertsAlexander Schuth is recorded as CFO at Denali Therapeutics Inc. (DNLI) since May 1, 2022. Alexander Schuth has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Denali Therapeutics Inc. on November 3, 2026. Denali Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Denali Therapeutics Inc. includes Ryan J. Watts (CEO and Board Member), Steve E. Krognes (CFO and Board Member), Alexander O. Schuth (COO) and 7 others.
“I will briefly review our portfolio strategy and pipeline priorities and then get to the financial results. Slide 21. The transport vehicle technology has broad potential for a wide range of indications where improved distribution of biologic medicines to the brain and other tissues can be beneficial.”
“I will close our prepared remarks today with a look at our portfolio, capital allocation priorities, and second quarter financial results. We have built a broad portfolio based on the transport vehicle platform, which is now clinically and commercially validated through AvLea.”
“We're very pleased about the interest, about the engagement, about the enthusiasm in this product and also what's coming in the pipeline. What is expected in a rare disease launch, especially in a buy and build setting, is that prescription activity will outpace revenues in the early stages of the launch.”
“We're very pleased about the interest, about the engagement, about the enthusiasm in this product and also what's coming in the pipeline. What is expected in a rare disease launch, especially in a buy and build setting, is that prescription activity will outpace revenues in the early stages of the launch.”
2022-05-01–present
Biotechnology · Healthcare
CFO
2022-05-01–present
